News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ares Life SciencesHolds 73.18% of the Capital and Voting Rights of Stallergenes, S.A. (GENP.PA) At the End of the Offering Period


3/17/2011 11:13:57 AM

Geneva, March 17, 2011: Ares Life Sciences, a healthcare-focused investment firm, announced that it holds as of today 73.18% of the capital and voting rights of Stallergenes.

In November 2010, Ares Life Sciences acquired Wendel’s equity stake in Stallergenes, representing 46% of the company’s share capital and voting rights, at a price of €59.00 per share. Following this transaction and in compliance with the existing regulation, Ares Life Sciences launched a mandatory takeover offer for all remaining outstanding shares of Stallergenes at the same price of €59.00 per share in cash. The offering period closed on Friday March 11, 2011.

About Ares Life Sciences

Ares Life Sciences is a healthcare-focused investment firm, whose financial backer is the Bertarelli family. Its strategy is to focus on key life sciences sectors, mainly: pharmaceuticals and biotechnology, medical diagnostics, and medical technology (MedTech). Ares Life Sciences has a long-term view on investments and a core element of its investment strategy is to make available to its portfolio companies the collective experience and network of its team in the healthcare sector. Ares Life Sciences’ portfolio currently includes investments in, Euromedic, Esaote, Santhera and Broncus.

About Stallergenes

Stallergenes is a European biopharmaceutical laboratory specialising in treatments by immunotherapy for the treatment of allergy-related respiratory conditions, such as rhino conjunctivitis, rhinitis and allergic asthma. A pioneer and a leader in immunotherapy treatments by sublingual administration, Stallergenes dedicates more than 20% of its gross sales to its research and development activities, which are primarily directed at developing a new therapeutic range: immunotherapy treatments by sublingual tablets. Stallergenes achieved 2010 sales of €216 million, with over 500,000 patients treated with Stallergenes products.

Contact persons :

Christophe Lamps - Dynamics Group Rue des Caroubiers 21, Geneva, Switzerland Tel:+41 22 308 62 20 Mob: +41 79 476 26 87 Fax: +41 22 308 62 36 E-mail: cla@dynamicsgroup.ch

Brunswick Agnes Catineau/Marie-Laurence Bouchon Tel: +33 1 53 96 83 83 Jon Coles Tel: +44 20 7396 5312

Paco Latorre - Ares Life Sciences Avenue Guiseppe Motta 31-33, CH- 1211 Geneva 20, Switzerland Tel: +41 79 5716207 E-mail: media@areslifesciences.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES